No Prescription |
 |
 | ||
|
Xylocaine Jelly Generic Lignocaine |
|
| ||
No Prescription » Prescription Drugs 17 » Xylocaine Jelly Generic Lignocaine This medication is used to prevent and control pain during certain medical procedures such as inserting a tube into the mouth nose throat or urinary tract (e.g. endotracheal intubation urinary catheterization). Lidocaine jelly is also used to numb and treat inflammation of the urinary tract (urethritis). Lidocaine is a topical anesthetic that numbs mucus membranes. It does not work to numb thicker skin. Buy Xylocaine Jelly Generic Lignocaine and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Xylocaine Jelly Generic Lignocaine: Product Type: Prescription Drugs 17 Xylocaine Jelly ( Generic Lignocaine ) Xylocaine Jelly (Generic Lignocaine) Generic Lignocaine 2%w/v Generic Lignocaine Xylocaine Jelly
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
